SEBI ICDR · LODR · Companies Act 2013

IPO
Compliance
Intelligence

AI-powered forensic analysis of DRHP, RHP & Prospectus. Section-by-section compliance verdicts. Audit trail violations, director remuneration, RPT breaches — detected automatically.

Live Compliance Preview
AUDIT TRAIL
🚨 VIOLATED
CA2013 Rule 11(g)
OFFER STRUCTURE
✅ MET
ICDR Reg.6,9,26
DIRECTOR PAY
⚠️ REVIEW
CA2013 Sec.197
VERDICT
⚠️ HIGH RISK
7.2/10 score
🔬 FORENSIC FINDING
Audit trail compliance omitted despite CA2013 Rule 11(g) mandatory since FY2023-24.
What IPO.Analyst Does

Professional-grade IPO forensics

Reads your actual PDF — all 500+ pages — and gives you compliance verdicts, not generic checklists

📋
Full PDF Coverage

Smart section extraction reads all 500+ pages in 4 targeted zones. Cover/Offer, Risk+Management, Financial Statements, Legal+Terms.

🚨
Critical Alert Detection

Auto-detects: Audit trail violations (Rule 11(g)), director pay excess (Sec.197), RPT breaches (Sec.188), auditor changes, qualified opinions.

Regulation Verdicts

Every SEBI regulation: MET ✅ or VIOLATED 🚩. Each verdict includes exact document quote, why it matters, and investor action.

🔬
6-Lens Analysis

Same IPO from six perspectives: Forensic Analyst, SEBI Regulator, CXO/Board, Investment Analyst, CA Trainer, and Student.

📊
SWOT + C-Suite Advisory

SWOT and decision matrix for CEO/CFO/COO level — backed by document evidence, not generic commentary.

🎯
Final Verdict

INVESTIBLE / HIGH RISK / AVOID with score out of 10 and supporting evidence. Supports — not replaces — professional advice.

Regulatory Framework

Every regulation. Checked.

SEBI ICDR 2018
IPO Disclosure & Requirements

The master regulation governing every Indian IPO — eligibility, disclosure, offer structure, pricing, promoter lock-in, and post-issue obligations.

Reg.6 — IPO eligibility: standard vs alternate route
Reg.9 — OFS sellers must disclose WAC
Reg.11 — Price [●] in DRHP is NORMAL
Reg.26 — Objects specific; GCP ≤ 25%
Ch.3 — Master disclosure checklist
SEBI LODR 2015
Listed Entity Obligations

Post-listing governance obligations operational from Day 1 — board composition, continuous disclosure, RPT policy, investor grievance.

Reg.17 — Board: ≥1/3 independent, 1 woman director
Reg.30 — Material events within 24 hours
Ch.VI-B — RPT >₹1,000Cr: shareholder approval
Ch.II-A — Quarterly shareholding disclosure
Ch.VI-F — Investor grievances within 15 days
Companies Act 2013
Corporate Law Framework

India's primary corporate statute — financial reporting, auditor duties, director accountability, and criminal liability for prospectus misstatements.

Rule 11(g) — Audit trail mandatory from FY2023-24
Sec.197 — Director pay cap: 11% net profit
Sec.188 — RPTs need board + shareholder approval
Sec.34 — False prospectus: jail up to 10 years
Sec.139 — Auditor rotation; unexplained change = red flag
Simple Pricing

Pay per analysis. No subscription.

Each credit = one full IPO analysis (DRHP + RHP + Prospectus). Credits never expire.

Starter
₹499
5 analysis credits · ₹99.8/analysis
5 full IPO analyses
DRHP + RHP + Prospectus
All 500+ pages read
Critical alerts + Verdicts
Credits never expire
Most Popular
Professional
₹999
12 analysis credits · ₹83.3/analysis
12 full IPO analyses
Everything in Starter
SWOT + C-Suite advisory
6-lens analysis
Priority email support
Institutional
₹1,999
30 analysis credits · ₹66.6/analysis
30 full IPO analyses
Everything in Professional
Team access (3 users)
Dedicated support
Custom regulation uploads
🔒 Secured by Razorpay ✅ Credits never expire 📧 puratanbharti@gmail.com ⚠️ Not investment advice
Our Team

Built by practitioners

Decades of combined experience in SEBI litigation, IPO compliance, capital markets advisory, and investor education

Arun Goenka
Arun Goenka
Founder — SIREN
Core Committee Member · WIRC of ICAI 2025-26

Five decades of hands-on experience in corporate litigation, stock broking and financial advisory. Has fought cases with and against SEBI; represented companies at SEBI and SAT. Origins of many SEBI regulatory changes trace back to his representations.

Founder of SIREN (Small Investors Rights Enforcement Association). Nominated as member of the "Corporate Laws and Corporate Governance Committee" of WIRC of ICAI for 2025-26.

SEBI Litigation SAT ICAI WIRC
Puratan Bharti
Puratan Bharti
Founder & CEO — Practical Financial Analyst Institute
NSE · NSE Academy · NISM · NSDL Empanelled Trainer

Over 15 years helping Indian SMEs grow through strategic guidance and financial resources. Evaluates investments — assessing financial health, management quality, and market opportunities.

Mentor at ATL (NITI Aayog). Empanelled trainer with NSE, NSE Academy, NISM & NSDL. Designed capital market training for DBS Group, Kotak Mahindra Bank, Axis Securities. Regular guest speaker at IIMs. Member — Entrepreneurship Club, Jagran Lakecity University. Former Board of Studies Member, Symbiosis Arts & Commerce College.

NSE Trainer NITI Aayog ATL IIM Speaker
Abhishek Pradhan
Abhishek Pradhan
Senior M&A Professional
Cross-border M&A · Family Offices · UHNI Advisory

Over 17 years of experience in cross-border M&A, Joint Ventures, and Capital Market investments. Evaluates investment opportunities for Ultra-High-Net-Worth Individuals, Family Offices, and Foreign Portfolio Investors.

Advises mid-corporates on growth through domestic and cross-border acquisitions, joint ventures, and technical collaborations. Deep expertise in structuring complex multi-jurisdictional transactions.

Cross-border M&A Family Offices FPI
Vaishnavi Mandhare
Vaishnavi Mandhare
Research Associate & Co-Author
CFA Level 1 · B.Com — Symbiosis Arts & Commerce College

CFA Level 1 passout with a B.Com from Symbiosis Arts & Commerce College. Currently interning with Stop Loss News on research work covering SEBI regulations, Companies Act 2013, and ROC compliance.

Vaishnavi brings fresh energy, hard work, and sharp analytical thinking to the team. She is presently co-authoring a book with Puratan Bharti on capital markets and compliance.

CFA L1 SEBI Research Co-Author Stop Loss News
📋 15 DRHP sections checked 🔬 6 forensic lenses 📄 All 500+ pages read 🎯 INVESTIBLE · HIGH RISK · AVOID
© 2025 IPO.Analyst · SIREN · Not investment advice · Powered by Claude AI